Clinical trials: Donor Lymphocyte Infusion
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort.
- Trial name
- NCT06529731
- Testing
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sawa Ito, MD
Hematologic Malignancy
Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant
The purpose of this study is to test the safety of adding donor dendritic cells to donor lymphocyte infusions, and to determine the type and severity of any side effects associated with this addition.
- Trial name
- NCT00476177
- Testing
- Infusion of donor dendritic cells, Infusion of donor lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Kidney Cancer
Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill cancer cells.
- Trial name
- NCT00025519
- Testing
- therapeutic allogeneic lymphocytes, fludarabine phosphate, mycophenolate mofetil
- Sponsor
- Fox Chase Cancer Center
Refractory Chronic Graft Versus Host Disease (cGVHD)
Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)
The present project is a prospective, multicenter, non-randomized, phase II trial which aims to evaluate the clinical impact and the safety of extracorporeal photopheresis (ECP) using the Theraflex system in patients with…
- Trial name
- NCT03083574
- Testing
- Photopheresis Theraflex ECP™
- Where
- 8 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Jules Bordet Institute
Leukemia
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells.
- Trial name
- NCT00005802
- Testing
- aldesleukin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancy
Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy
Allo-hsct is potentially curative method of treatment for children and adolescent with hematologic malignancy. However, relapses of disease after allo-hsct occur up to 50% of patients and constitute the main cause of mortality…
- Trial name
- NCT05009719
- Testing
- Prophylactic Donor lymphocytes infusions, Preventive Donor lymphocytes infusions
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Leukemia, Myelodysplastic Syndromes
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
RATIONALE: Giving total-body irradiation and chemotherapy, such as thiotepa and fludarabine, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Trial name
- NCT00376480
- Testing
- anti-thymocyte globulin, peripheral blood lymphocyte therapy, fludarabine phosphate
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of donor lymphocyte infusions when given together with daratumumab and to see how well they work in treating participants with acute myeloid leukemia that has come back…
- Conditions
- Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT03537599
- Testing
- Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sumithira Vasu
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant
RATIONALE: Vaccines made from the patient's cancer cells may help the body build an effective immune response to kill cancer cells.
- Trial name
- NCT00469820
- Testing
- autologous tumor cell vaccine, peripheral blood lymphocyte therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hematologic Malignancies
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
This study is being done to assess the safety and determine the maximum tolerable dose (MTD) of TCRαβ+/CD19+-depleted Donor Lymphocyte Infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in highrisk patients…
- Trial name
- NCT07285668
- Testing
- Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Wisconsin, Madison
Relapse Acute Myeloid Leukemia
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
This clinical trial included 30 cases and aimed to understand the effectiveness and safety of the VMAC regimen combined with donor lymphocyte infusion (DLI) in the treatment of patients with acute myeloid leukemia who have…
- Trial name
- VMAC+DLI (NCT06447090)
- Testing
- Mitoxantrone hydrochloride liposome
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation
This is a new platform in non-myeloablative allogeneic stem cell transplantation to improve survival by harnessing the immunologic potential of donor T-cells to induce and maintain long-term remissions in patients with…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00374933
- Testing
- Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI, "Prophylactic" delayed ADLI, "Prophylactic" delayed activated donor lymphocyte infusion
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hematopoietic Organs; Disorder
CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation
In this clinical trial, the investigators aim to apply CD62L depleted donor lymphocyte infusion (DLI) together with in vitro T cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) to treat patients with…
- Trial name
- NCT06034535
- Testing
- CD62L depleted donor lymphocyte infusion
- Where
- Hong Kong
- Volunteers
- 23 people
- Sponsor
- Hong Kong Children's Hospital
Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Two key methods of GVHD prevention in allogeneic HSCT have a number of limitations: ex vivo T depletion is associated with an excess of infectious complications, and pharmacological immunosuppression with insufficient efficacy of…
- Conditions
- Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute Lymphoblastic Leukemia, Relapse
- Trial name
- NCT07366801
- Testing
- Cyclosporine A (CsA), Sirolimus, Ruxolitinib (JAKAVI®)
- Where
- Russia
- Volunteers
- 64 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Leukemia, Myeloid, Chronic, Lymphomas
Post Transplant Donor Lymphocyte Infusion
The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.
- Conditions
- Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
- Trial name
- NCT00167180
- Testing
- Donor Lymphocyte Infusion, Induction Chemotherapy
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematologic Malignancies
Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies
The purpose of this research study is to evaluate the safety and efficacy of cell depletion in a donor lymphocyte infusion (DLI) product with the use of the CliniMACS machine.
- Trial name
- NCT00675831
- Testing
- CliniMACS CD25 Reagent Device
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Haematologic Disease
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation
For several decades, allogeneic hematopoietic stem cell trans-plantation (allo-HSCT) has remained an important strategy in the management of patients with high-risk hematological malignancies.
- Trial name
- CTL-DP 01 (NCT04180059)
- Testing
- CTL 19
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Nantes University Hospital
Graft Versus Host Disease, Leukemia
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myeloma
- Trial name
- ProT4 (NCT01240525)
- Testing
- CD4 DLI, No DLI
- Where
- 11 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- University College, London
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy
The trial will be conducted as a multicentre open label, randomised prospective phase II clinical trial in patients with high risk myeloid malignancies.
- Trial name
- PRO-DLI (NCT02856464)
- Testing
- DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism), DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice
- Where
- United Kingdom
- Volunteers
- 124 people
- Sponsor
- King's College Hospital NHS Trust
Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Prophylactic DLI-X for Leukemia Relapse After HCT
The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo)…
- Conditions
- Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome
- Trial name
- NCT07254793
- Testing
- Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Arizona